Setara Biosciences announced a USD 90 million Series A on 30 October 2026. Deerfield Management, Canaan, Droia Ventures, EcoR1 Capital, Euclidean Capital, Regeneron Ventures and Jazz Venture Partners joined the financing, with no lead identified. David Goldstein and David Breckenridge cofounded Setara after working together at Actio Biosciences. Setara is developing precision medicines for rare genetic diseases. Its lead programme, STAR-0871, has completed the healthy volunteer portion of a Phase 1 trial, with patient studies planned in 2027. The proceeds will support that programme and additional discovery work. The amount is current round funding, not a valuation or cumulative total.
Setara Biosciences raises USD 90m Series A
Seven investors back precision medicines for rare genetic diseases

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


